In 2024, Santen Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Santen Pharmaceutical has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 17,372a | 17,021a | 16,948a | |
Total Scope 2 | ||||
Market-Based | 17,498a | 5,417a | 5,671a | |
Location-Based | 35,574a | 22,591a | 21,390a | |
Total Scope 3 | 154,563a | 196,579a | 133,451a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 8.7123a | 8.1251a | 7.767a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Santen Pharmaceutical amounted to 52,946 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Santen Pharmaceutical increased by 33.66%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Santen Pharmaceutical were 17,372 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Santen Pharmaceutical's Scope 1 emissions have remained relatively, stable, indicating that Santen Pharmaceutical's emissions have plateaued with no significant change in its operational footprint.a
Compared to the previous year (2023), Santen Pharmaceutical's Scope 1 emissions increased by 2.06%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, Santen Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 17,498 tCO₂e using the market-based method and 35,574 tCO₂e using the location-based method.a
Since 2019, Santen Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 76.22%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2023), Santen Pharmaceutical's Scope 2 emissions (Location-Based) rose by 57.47% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2024, Santen Pharmaceutical reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Santen Pharmaceutical reported 154,563 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Santen Pharmaceutical includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Santen Pharmaceutical reported total Scope 3 emissions of 154,563 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.77% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.23% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Santen Pharmaceutical's Scope 3 emissions have increased by 19.54%, reflecting a rising long-term trend in Scope 3 emissions over time.a
Compared to the previous year (2023), Santen Pharmaceutical's Scope 3 emissions decreased by 21.37%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2024, Santen Pharmaceutical reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2024, the largest contributors to Santen Pharmaceutical's Scope 3 emissions were:a
In 2024, Santen Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 17,372 tCO₂e and total revenues of USD 1,994 millions. This translates into an emissions intensity of 8.71 tCO₂e per millions USD.a
In 2024, Santen Pharmaceutical reported a Scope 1 emissions intensity of 8.71 tCO₂e per millions USD. Compared to the peer group median of 4.98, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Santen Pharmaceutical ranked 19 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Santen Pharmaceutical among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2024, Santen Pharmaceutical reported a total carbon footprint of 207,509 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12.14% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Santen Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 74.48% of the company's total carbon footprint, followed by Scope 2 emissions at 17.14%.a